Trial Profile
A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Behcet's syndrome
- Focus Adverse reactions
- Acronyms AMORE
- Sponsors AbbVie
- 22 Apr 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 16 May 2018 Planned number of patients changed from 60 to 120.